Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Dyadic International ( (DYAI) ).
Dyadic International has secured a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effective monoclonal antibodies targeting RSV and malaria using its C1 protein production platform. This initiative aims to enhance global access to affordable treatments for these diseases, which heavily impact low-income countries. By leveraging the C1 platform’s efficiency, Dyadic seeks to reduce production costs and improve accessibility to crucial therapeutics, addressing significant health disparities.
See more insights into DYAI stock on TipRanks’ Stock Analysis page.